Science

Yuji Uehara: Resistance to osimertinib in EGFR-mutated LUAD

Yuji Uehara/X

Dec 20, 2024, 14:12

Yuji Uehara: Resistance to osimertinib in EGFR-mutated LUAD

Yuji Uehara, Medical Oncologist, National Cancer Center, Japan, shared a post on X about a recent study by him and colleagues published in Journal of Thoracic Oncology:

“Hot Off the Press from our study: Solid histology and high podoplanin CAFs predict resistance to osimertinib in EGFR-mutated LUAD.

Key Findings:

Solid histology/High podoplanin CAFs: Worse PFS and OS for Osimertinib – HGF Expression is higher in these tumors.
Could identify patients for intensive therapy targeting MET + EGFR (e.g., Ami + Lazer).”

Solid predominant histology and high podoplanin expression in cancer-associated fibroblast predict primary resistance to osimertinib in EGFR-mutated lung adenocarcinoma

Authors: Yuji Uehara et al.

Yuji Uehara: Resistance to osimertinib in EGFR-mutated LUAD

More posts featuring Yuji Uehara.

cancer EGFR-mutated LUAD Eri Sugiyama Genichiro Ishi Hibiki Udagawa Hiroki Izumi Keiju Aokage Kiyotaka Yoh Koichi Goto lung adenocarcinoma Masahiro Tsuboi Michiko Nagamine Motohiro Kojima Naoya Sakamoto OncoDaily Oncology osimertinib Shigeki Umemura Shingo Matsumoto Shingo Sakashita Shoko Kubota Tetsuro Taki Tetsuya Sakai Yoshitaka Zenke Yuji Uehara Yukio Hosomi

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage